Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

296,894 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy.
Daoudlarian D, Segot A, Latifyan S, Bartolini R, Joo V, Mederos N, Bouchaab H, Demicheli R, Abdelhamid K, Ferahta N, Doms J, Stalder G, Noto A, Mencarelli L, Mosimann V, Berthold D, Stravodimou A, Sartori C, Shabafrouz K, Thompson JA, Wang Y, Peters S, Pantaleo G, Obeid M. Daoudlarian D, et al. Among authors: wang y. Ann Oncol. 2024 Dec 17:S0923-7534(24)04979-2. doi: 10.1016/j.annonc.2024.12.004. Online ahead of print. Ann Oncol. 2024. PMID: 39701282 Free article.
Sclerosing mesenteritis following immune checkpoint inhibitor therapy.
Kuang AG, Sperling G, Liang TZ, Lu Y, Tan D, Bollin K, Johnson DB, Manzano JM, Shatila M, Thomas AS, Thompson JA, Zhang HC, Wang Y. Kuang AG, et al. Among authors: wang y. J Cancer Res Clin Oncol. 2023 Sep;149(11):9221-9227. doi: 10.1007/s00432-023-04802-2. Epub 2023 May 17. J Cancer Res Clin Oncol. 2023. PMID: 37195298
Immune Checkpoint Inhibitor-Induced Colitis.
S Thomas A, Lu Y, Campbell M, Thompson JA, Tan D, Faleck DM, Wang Y. S Thomas A, et al. Among authors: wang y. Gastroenterology. 2025 Jan;168(1):21-28. doi: 10.1053/j.gastro.2024.09.034. Epub 2024 Oct 9. Gastroenterology. 2025. PMID: 39389184 No abstract available.
Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events.
Shatila M, Zhang HC, Shirwaikar Thomas A, Machado AP, Naz S, Mittal N, Catinis C, Varatharajalu K, Colli Cruz C, Lu E, Wu D, Brahmer JR, Carbonnel F, Hanauer SB, Lashner B, Schneider B, Thompson JA, Obeid M, Farris DP, Wang Y. Shatila M, et al. Among authors: wang y. J Immunother Cancer. 2024 Nov 14;12(11):e009742. doi: 10.1136/jitc-2024-009742. J Immunother Cancer. 2024. PMID: 39542654 Free PMC article.
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
Zou F, Faleck D, Thomas A, Harris J, Satish D, Wang X, Charabaty A, Ernstoff MS, Glitza Oliva IC, Hanauer S, McQuade J, Obeid M, Shah A, Richards DM, Sharon E, Wolchok J, Thompson J, Wang Y. Zou F, et al. Among authors: wang x, wang y. J Immunother Cancer. 2021 Nov;9(11):e003277. doi: 10.1136/jitc-2021-003277. J Immunother Cancer. 2021. PMID: 34789551 Free PMC article.
Characteristics, treatment, and outcome of diverticulitis after immune checkpoint inhibitor treatment in patients with malignancies.
Thomas AR, Eyada M, Kono M, Varatharajalu K, Lu Y, Xu G, Panneerselvam K, Shatila M, Altan M, Wang J, Thompson JA, Zhang HC, Khan MA, Raju GS, Thomas AS, Wang Y. Thomas AR, et al. Among authors: wang j, wang y. J Cancer Res Clin Oncol. 2023 Jul;149(8):4805-4816. doi: 10.1007/s00432-022-04405-3. Epub 2022 Oct 15. J Cancer Res Clin Oncol. 2023. PMID: 36242603
296,894 results
You have reached the last available page of results. Please see the User Guide for more information.